Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is 1 of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced affirmative interim Phase 1 results for SPY003, which is its novel, half-life extended Anti-IL-23 antibody. The attraction is being tested for curing inflammatory bowel illness and rheumatic diseases.

​During the trial, SPY003 showed a half-life of astir 85 days, supporting attraction dosing of 3 oregon six months. Management noted that the proceedings was randomized, double-blind, and placebo-controlled with 59 steadfast volunteers astatine assorted doses. In addition, the cause besides demonstrated a favourable information profile, with nary superior adverse events.

​On the aforesaid day, Julian Harrison of BTIG maintained Spyre Therapeutics, Inc. (NASDAQ:SYRE) with a Buy standing and a $70 terms target. He noted that the extended half-life supports little predominant dosing, which is simply a captious advancement for SPY003 arsenic a invaluable constituent successful operation therapies.

​Moreover, Harrison besides mentioned the company’s unsocial quality to harvester aggregate monoclonal antibodies into a azygous treatment. In presumption of finances, the expert noted the institution to beryllium well-positioned with a important currency runway to money operations till the 2nd fractional of 2028.

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is simply a clinical-stage biotechnology institution that develops antibody-based therapies for inflammatory bowel illness and different immune-related conditions.

While we admit the imaginable of SYRE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.